The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials

Basit Öğe Kaydı
dc.authorscopusidTevfik Ecder / 6701719246
dc.authorwosidTevfik Ecder / EUG-3311-2022
dc.contributor.authorArıcı, Mustafa
dc.contributor.authorAltun, Bülent
dc.contributor.authorAraz, Mustafa
dc.contributor.authorAtmaca, Ayşegül
dc.contributor.authorDemir, Tevfik
dc.contributor.authorEcder, Tevfik
dc.contributor.authorGüz, Galip
dc.contributor.authorGogas Yavuz, Dilek
dc.contributor.authorYıldız, Alaattin
dc.contributor.authorYılmaz, Temel
dc.date.accessioned2025-04-18T09:01:16Z
dc.date.available2025-04-18T09:01:16Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractThis scoping review prepared by endocrinology and nephrology experts aimed to address the significance of finerenone, as a novel therapeutic option, in diabetic kidney disease (DKD), based on the biological prospect of cardiorenal benefit due to non-steroidal mineralocorticoid receptor antagonist (MRA) properties, and the recent evidence from the finerenone phase 3 program clinical trials. The importance of finerenone in slowing DKD progression was critically reviewed in relation to the role of MR overactivation in the pathogenesis of cardiorenal disease and unmet needs in the current practice patterns. The efficacy and safety outcomes of finerenone phase III study program including FIDELIO-DKD, FIGARO-DKD and FIDELITY were presented. Specifically, perspectives on inclusion of patients with preserved estimated glomerular filtration rate (eGFR) or high albuminuria, concomitant use of sodium-glucose co-transporter-2 inhibitor (SGLT2i) or glucagon-like peptide 1 receptor agonist (GLP-1 RA), baseline glycated hemoglobin (HbA1c) level and insulin treatment, clinically meaningful heart failure outcomes and treatment-induced hyperkalemia were addressed. Finerenone has emerged as a new therapeutic agent that slows DKD progression, reduces albuminuria and risk of cardiovascular complications, regardless of the baseline HbA1c levels and concomitant treatments (SGLT2i, GLP-1 RA, or insulin) and with a favorable benefit-risk profile. The evolving data on the benefit of SGLT2is and non-steroidal MRAs in slowing or reducing cardiorenal risk seem to provide the opportunity to use these pillars of therapy in the management of DKD, after a long-period of treatment scarcity in this field. Along with recognition of the albuminuria as a powerful marker to detect those patients at high risk of cardiorenal disease, these important developments would likely to impact standard-of-care options in the setting of DKD.
dc.description.sponsorshipBayer Turkey KAPPA Training Consultancy Research LLC
dc.identifier.citationArici, M., Altun, B., Araz, M., Atmaca, A., Demir, T., Ecder, T., ... & Yilmaz, T. (2024). The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials. Frontiers in Medicine, 11, 1384454.
dc.identifier.doi10.3389/fmed.2024.1384454
dc.identifier.endpage19
dc.identifier.issn2296858X
dc.identifier.pmid38947237
dc.identifier.scopus2-s2.0-85197377744
dc.identifier.scopusqualityQ1
dc.identifier.startpage1
dc.identifier.urihttp://dx.doi.org/10.3389/fmed.2024.1384454
dc.identifier.urihttps://hdl.handle.net/20.500.12713/6666
dc.identifier.volume11
dc.identifier.wosWOS:001256845400001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorEcder, Tevfik
dc.institutionauthoridTevfik Ecder / 0000-0003-3394-5775
dc.language.isoen
dc.publisherFrontiers media SA
dc.relation.ispartofFrontiers in medicine
dc.relation.ispartofserieshttp://dx.doi.org/
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCardiorenal Risk
dc.subjectDiabetic Kidney Disease
dc.subjectEfficacy
dc.subjectFinerenone
dc.subjectMR Antagonists
dc.subjectMR Overactivation
dc.subjectSafety
dc.subjectType 2 Diabetes
dc.titleThe significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials
dc.typeOther

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
The-significance-of-finerenone-as-a-novel-therapeutic-option-in-diabetic-kidney-disease-a-scoping-review-with-emphasis-on-cardiorenal-outcomes-of-the-finerenone-phase-3-trialsFrontiers-in-Medicine.pdf
Boyut:
2.93 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Diğer Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu